Cargando…
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
Histone deacetylase inhibitors (HDIs) represent a new class of anticancer drugs. Suberoylanilide hydroxamic acid (SAHA), the first HDI approved for the treatment of cutaneous T cell lymphoma (CTCL), is currently being tested in clinical trials for other cancers. However, SAHA has been ineffective ag...
Autores principales: | Wang, Qun, Tan, Rong, Zhu, Xin, Zhang, Yi, Tan, Zhiping, Su, Bing, Li, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891104/ https://www.ncbi.nlm.nih.gov/pubmed/26848526 http://dx.doi.org/10.18632/oncotarget.7134 |
Ejemplares similares
-
Phosphorus containing analogues of SAHA as inhibitors of HDACs
por: Pun, Michael D., et al.
Publicado: (2022) -
Molecular Analysis of Oncogenes, ras Family Genes (N‐ras, K‐ras, H‐ras), myc Family Genes (c‐myc, N‐myc) and mdm2 in Natural Killer Cell Neoplasms
por: Sugimoto, Kei‐ji, et al.
Publicado: (2002) -
Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
por: Tran, Phuoc T., et al.
Publicado: (2008) -
K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc
por: Magudia, Kirti, et al.
Publicado: (2012) -
Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)